PATENT CLAIM ANALYSIS

Application Number: 16248449
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "226500"]

Abstract:
Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.

Claim (Index 1):
A method of treating migraine comprising: orally administering a solid dosage form once daily to a human being suffering from a migraine, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether \u03b2-cyclodextrin (SBE\u03b2CD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a T max  of meloxicam that is shorter than a T max  of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBE\u03b2CD, and 3) does not contain a bicarbonate, wherein the solid dosage form has been shown to have a median T max  of meloxicam that is less than 2 hours in human subjects.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.35135
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15902770', '15989734', '16247406', '15986215', '15797955']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8247233843382411
- 35 USC 102 Novelty (BERT): 0.5399693257552145
- Combined Prediction Score: 0.7962479784799384
- Mean Citation Score: 381.179248
- Max Citation Score: 385.98938
- Similarity Product: 381.6522836676097

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test